Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Denali Therapeutics Inc has a consensus price target of $41.95 based on the ratings of 22 analysts. The high is $87 issued by HC Wainwright & Co. on January 7, 2025. The low is $24 issued by JP Morgan on January 7, 2025. The 3 most-recent analyst ratings were released by Deutsche Bank, Goldman Sachs, and JP Morgan on February 11, 2025, January 28, 2025, and January 7, 2025, respectively. With an average price target of $31.67 between Deutsche Bank, Goldman Sachs, and JP Morgan, there's an implied 50.87% upside for Denali Therapeutics Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Denali Therapeutics (NASDAQ:DNLI) was reported by Deutsche Bank on February 11, 2025. The analyst firm set a price target for $31.00 expecting DNLI to rise to within 12 months (a possible 47.69% upside). 26 analyst firms have reported ratings in the last year.
The latest analyst rating for Denali Therapeutics (NASDAQ:DNLI) was provided by Deutsche Bank, and Denali Therapeutics initiated their buy rating.
The last upgrade for Denali Therapeutics Inc happened on December 16, 2024 when Stifel raised their price target to $37. Stifel previously had a hold for Denali Therapeutics Inc.
There is no last downgrade for Denali Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Denali Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Denali Therapeutics was filed on February 11, 2025 so you should expect the next rating to be made available sometime around February 11, 2026.
While ratings are subjective and will change, the latest Denali Therapeutics (DNLI) rating was a initiated with a price target of $0.00 to $31.00. The current price Denali Therapeutics (DNLI) is trading at is $20.99, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.